Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death

Imagem de Miniatura
Arquivos
art_REGUEIRO_Association_Between_Transcatheter_Aortic_Valve_Replacement_and_Subsequent_2016.PDF (316.77 KB)
Citações na Scopus
248
Tipo de produção
article
Data de publicação
2016
Editora
AMER MEDICAL ASSOC
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
REGUEIRO, Ander
LINKE, Axel
LATIB, Azeem
IHLEMANN, Nikolaj
URENA, Marina
WALTHER, Thomas
HUSSER, Oliver
HERRMANN, Howard C.
NOMBELA-FRANCO, Luis
CHEEMA, Asim N.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, v.316, n.10, p.1083-1092, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
IMPORTANCE Limited data exist on clinical characteristics and outcomes of patients who had infective endocarditis after undergoing transcatheter aortic valve replacement (TAVR). OBJECTIVE To determine the associated factors, clinical characteristics, and outcomes of patients who had infective endocarditis after TAVR. DESIGN, SETTING, AND PARTICIPANTS The Infectious Endocarditis after TAVR International Registry included patients with definite infective endocarditis after TAVR from 47 centers from Europe, North America, and South America between June 2005 and October 2015. EXPOSURE Transcatheter aortic valve replacement for incidence of infective endocarditis and infective endocarditis for in-hospital mortality. MAIN OUTCOMES AND MEASURES Infective endocarditis and in-hospital mortality after infective endocarditis. RESULTS A total of 250 cases of infective endocarditis occurred in 20 006 patients after TAVR (incidence, 1.1% per person-year; 95% Cl, 1.1%44%; median age, 80 years; 64% men). Median time from TAVR to infective endocarditis was 5.3 months (interquartile range [IQR], 1.5-13.4 months). The characteristics associated with higher risk of progressing to infective endocarditis after TAVR was younger age (78.9 years vs 81.8 years; hazard ratio [HR], 0.97 per year; 95% CI, 0.94-0.99), male sex (62.0% vs 49.7%; HR, 1.69; 95% C1,1.13-2.52), diabetes mellitus (41.7% vs 30.0%; HR, 1.52; 95% Cl, 1.02-2.29), and moderate to severe aortic regurgitation (22.4% vs 14.7%; HR, 2.05; 95% Cl, 1.28-3.28). Health care-associated infective endocarditis was present in 52.8% (95% Cl, 46.6%-59.0%) of patients. Enterococci species and Staphylococcus aureus were the most frequently isolated microorganisms (24.6%; 95% Cl, 19.1%-30.1% and 23.3%; 95% Cl, 17.9%-28.7%, respectively). The in-hospital mortality rate was 36% (95% Cl, 30.0%-41.9%; 90 deaths; 160 survivors), and surgery was performed in 14.8% (95% Cl, 10.4%-19.2%) of patients during the infective endocarditis episode. In-hospital mortality was associated with a higher logistic EuroSCORE (23.1% vs 18.6%; odds ratio [OR], 1.03 per 1% increase; 95% C1,1.00-1.05), heart failure (59.3% vs 23.7%; OR, 3.36; 95% Cl, 1.74-6.45), and acute kidney injury (67.4% vs 31.6%; OR, 2.70; 95% C1,1.42-5.11). The 2-year mortality rate was 66.7% (95% Cl, 59.0%-74.2%; 132 deaths; 115 survivors). CONCLUSIONS AND RELEVANCE Among patients undergoing TAVR, younger age, male sex, history of diabetes mellitus, and moderate to severe residual aortic regurgitation were significantly associated with an increased risk of infective endocarditis. Patients who developed endocarditis had high rates of in-hospital mortality and 2-year mortality.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/17260
Referências
  1. AGNIHOTRI AK, 1995, J THORAC CARDIOV SUR, V110, P1708, DOI 10.1016/S0022-5223(95)70035-8
  2. Akowuah EF, 2003, HEART, V89, P269, DOI 10.1136/heart.89.3.269
  3. Amat-Santos IJ, 2015, CIRCULATION, V131, P1566, DOI 10.1161/CIRCULATIONAHA.114.014089
  4. Amat-Santos IJ, 2015, JACC-CARDIOVASC INTE, V8, P334, DOI 10.1016/j.jcin.2014.09.013
  5. Athappan G, 2013, J AM COLL CARDIOL, V61, P1585, DOI 10.1016/j.jacc.2013.01.047
  6. Baddour LM, 2003, CIRCULATION, V108, P2015, DOI 10.1161/01.CIR.0000093201.57771.47
  7. CALDERWOOD SB, 1985, CIRCULATION, V72, P31
  8. Chirouze C, 2015, CLIN INFECT DIS, V60, P741, DOI 10.1093/cid/ciu871
  9. Friedman ND, 2002, ANN INTERN MED, V137, P791
  10. Habib G, 2015, EUR HEART J, V36, P3075, DOI 10.1093/eurheartj/ehv319
  11. Jerez-Valero M, 2014, JACC-CARDIOVASC INTE, V7, P1022, DOI 10.1016/j.jcin.2014.04.012
  12. Kang DH, 2012, NEW ENGL J MED, V366, P2466, DOI 10.1056/NEJMoa1112843
  13. Kappetein AP, 2012, J AM COLL CARDIOL, V60, P1438, DOI 10.1016/j.jacc.2012.09.001
  14. Kodali SK, 2012, NEW ENGL J MED, V366, P1686, DOI 10.1056/NEJMoa1200384
  15. Lalani T, 2013, JAMA INTERN MED, V173, P1495, DOI 10.1001/jamainternmed.2013.8203
  16. Latib A, 2014, J AM COLL CARDIOL, V64, P2176, DOI 10.1016/j.jacc.2014.09.021
  17. Leone S, 2016, INFECTION, V44, P273, DOI 10.1007/s15010-015-0836-0
  18. Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753
  19. Mangner N, 2016, J AM COLL CARDIOL, V67, P2907, DOI 10.1016/j.jacc.2016.03.588
  20. Martinez-Selles M, 2016, EUROINTERVENTION, V11, P1180, DOI 10.4244/EIJY15M02_05
  21. Movahed MR, 2007, J DIABETES COMPLICAT, V21, P403, DOI 10.1016/j.jdiacomp.2007.07.003
  22. Nishimura RA, 2014, J AM COLL CARDIOL, V63, P2438, DOI 10.1016/j.jacc.2014.02.537
  23. O'Connor SA, 2015, J AM COLL CARDIOL, V66, P221, DOI 10.1016/j.jacc.2015.05.024
  24. Olsen NT, 1939, CIRC-CARDIOVASC INTE, V8, DOI [10.1161/circinterventions.114.001939, DOI 10.1161/CIRCINTERVENTIONS.114]
  25. Pericas JM, 2015, J INFECTION, V70, P565, DOI 10.1016/j.jinf.2014.12.013
  26. Reardon MJ, 2015, J AM COLL CARDIOL, V66, P113, DOI 10.1016/j.jacc.2015.05.017
  27. RODBARD S, 1963, CIRCULATION, V27, P18
  28. Roques F, 2003, EUR HEART J, V24, P881, DOI 10.1016/S0195-668X(02)00799-6
  29. Wang A, 2007, JAMA-J AM MED ASSOC, V297, P1354, DOI 10.1001/jama.297.12.1354

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/11
Artigos e Materiais de Revistas Científicas - ODS/03